Vaccine Injury Support Program
Undoubtedly, vaccines are among the most crucial public health measures ever implemented. According to the World Health Organization (WHO), immunizations save 2.5 million lives annually and shield millions more from illness and disability. However, on very rare occasions, a serious adverse effect may occur from a vaccine. To address this, Canada has implemented the Vaccine Injury Support Program (VISP), ensuring that individuals who suffer serious or permanent injuries from Health Canada-authorized vaccines receive fair and timely financial support.
The VISP covers serious, life-threatening, or life-altering injuries that may require hospitalization or result in significant disability, congenital malformation, or death. Compensation is retroactive to the date of the injury, offering financial relief for medical expenses, rehabilitation costs, and other related financial burdens. This retroactive aspect underscores the program’s commitment to fair and comprehensive support for affected individuals.
Importantly, the VISP is accessible to individuals in all provinces and territories in Canada, except Québec. Residents of Québec will continue to benefit from their province’s longstanding Vaccine Injury Compensation Program. Notably, the VISP does not require Canadian citizenship for eligibility; the critical criterion is that the vaccine must have been administered within Canada.
To be eligible for compensation, individuals must submit their applications within three years. This timeline ensures that those affected have ample time to recognize and report their injuries while still allowing for timely support.
The Vaccine Injury Support Program is a significant step towards ensuring the safety and well-being of individuals who suffer from vaccine-related injuries. By providing a safety net for those affected, Canada demonstrates its dedication to public health and the importance of compassionate support. Understanding the VISP and its benefits is crucial for anyone receiving vaccines in Canada, as it offers reassurance and protection in the rare event of a serious adverse reaction.
Learn more here.
